drugset / Trial / NCT00154336
A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Imatinib is a member of a new class of drugs known as signal transduction inhibitors. The purpose of this study is to evaluate the efficacy, safety and tolerability of imatinib in the treatment of rheumatoid arthritis in combination with methotrexate in patients who do not respond satisfactorily to standard treatment, e.g. methotrexate.
Timeline
- Start
- 2004-07
- Primary completion
- 2005-08
- Completion
- 2005-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Imatinib | Small molecule | 400 mg | — |
| Comparator | Methotrexate | Small molecule | — | — |